FY 2020 Results & 2021 Outlook

Investor Presentation - February 24th, 2021

P I O N E E R I N G D I A G N O S T I C S

DISCLAIMER

This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.

The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.

This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.

2

AGENDA

OVERVIEW OF bioMérieux

FY 2020 ACTIVITY REVIEW

FY 2020 FINANCIAL RESULTS

CSR AMBITION

2021 OUTLOOK

KEY TAKEAWAYS - 2020 PERFORMANCE

SALES

€3,118m

+19.7%

at constant exchange rates and scope of consolidation

FREE CASH FLOW

€328m

4

PROFITABILITY

€613m

19.6%of sales vs. 14.5% in 2019

LEVERAGE

0.1x EBITDA

BUSINESS TRENDS

Molecular biology

Microbiology

Immunoassays

Industry

COMPREHENSIVE COVID-19

IN VITRO DIAGNOSTIC SOLUTION

EXTRACTION

PCR TEST

SYNDROMIC

SEROLOGY

ARGENE®

SARS-CoV-2R-GENE®

VIDAS®

EMAG® &

SARS-Cov-2 RESPI R-GENE®

BIOFIRE® RP2.1

anti-SARS-CoV-2 IgM

EASYMAG®

BIOFIRE® RP2.1plus

anti-SARS-CoV-2 IgG

High quality and fully

Ready-to-use kits with internal

Rapid, easy, automated syndromic

Fully automated qualitative assays

automated RNA extraction

controls allowing mid-to-high

testing of 22 or 23 pathogens

for the detection of antibodies

prior to amplification

size batch analyses on most

that cause respiratory infections,

in patients who have been exposed

and detection

real-time PCR systems. The

including SARS-CoV-2

to SARS-CoV-2

5

Single plex SARS-CoV-2R-GENE® may be used on saliva and oropharyngeal (throat) swab specimens

Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.

Attachments

  • Original document
  • Permalink

Disclaimer

BioMérieux SA published this content on 16 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 April 2021 09:35:05 UTC.